Page last updated: 2024-11-11

1-stearoyl-2-arachidonoylglycerol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-stearoyl-2-arachidonoylglycerol : A 1,2-diglyceride in which the acyl groups at positions 1 and 2 are specifed as stearoyl and arachidonoyl respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1-stearoyl-2-arachidonoyl-sn-glycerol : A 1,2-diacyl-sn-glycerol in which the acyl groups at positions 1 and 2 are specifed as stearoyl and arachidonoyl respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID14345637
CHEBI ID83288
SCHEMBL ID1412343
MeSH IDM0204123
PubMed CID6438587
CHEBI ID75728
SCHEMBL ID1009384
MeSH IDM0204123

Synonyms (53)

Synonym
1-stearoyl-2-arachidonoyl-sn-glycerol, ~98%, suitable for stimulation of protein kinase c derived from liver cells, liquid
1-stearoyl-2-arachidonoylglycerol
CHEBI:83288
1-hydroxy-3-(octadecanoyloxy)propan-2-yl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate
1-octadecanoyl-2-(5z,8z,11z,14z)-eicosatetraenoylglycerol
1-octadecanoyl-2-(5z,8z,11z,14z)-icosatetraenoylglycerol
SCHEMBL1412343
Q27156731
(1-hydroxy-3-octadecanoyloxypropan-2-yl) (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate
1-stearin-2-arachidonin-sn-glycerol
gtpl2437
dg(18:0_20:4)
dg(18:0/20:4/0:0)[iso2]
1-octadecanoyl-2-(5z,8z,11z,14z-eicosatetraenoyl)-sn-glycerol
LMGL02010111
dg(18:0/20:4(5z,8z,11z,14z)/0:0)[iso2]
IDI1_033877
BSPBIO_001407
1-stearoyl-2-arachidonoyl-sn-glycerol
NCGC00161335-01
NCGC00161335-02
NCGC00161335-03
65914-84-3
1-stearoyl-2-arachidonoyl-glycerol
HMS1989G09
BML2-F09
HMS1791G09
HMS1361G09
[(2s)-1-hydroxy-3-octadecanoyloxypropan-2-yl] (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate
(2s)-1-hydroxy-3-(octadecanoyloxy)propan-2-yl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate
dag(18:0/20:4omega6)
dag(18:0/20:4)
(2s)-1-hydroxy-3-(stearoyloxy)propan-2-yl (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoate
dg(18:0/20:4(5z,8z,11z,14z)/0:0)
CHEBI:75728
dg(18:0/20:4omega6)
dg(18:0/20:4(omega-6)/0:0)
diacylglycerol(18:0/20:4omega6)
diacylglycerol(18:0/20:4)
5,8,11,14-eicosatetraenoic acid, 1-(hydroxymethyl)-2-((1-oxooctadecyl)ethyl) ester, (s-(all-z))-
SCHEMBL1009384
HMS3402G09
AKOS027379145
dg(18:0/20:4w6)
dg(18:0/20:4n6)
dag(18:0/20:4w6)
diacylglycerol(18:0/20:4w6)
dag(18:0/20:4n6)
Q27088683
diacylglycerol(18:0/20:4n6)
HY-131897
DTXSID901286391
CS-0142415
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
1,2-diglyceride
1,2-diacyl-sn-glycerol
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (30)

PathwayProteinsCompounds
Activation of PKC Through G Protein-Coupled Receptor46
Phosphatidylcholine Biosynthesis PC(18:0/20:4(5Z,8Z,11Z,14Z))620
Phosphatidylethanolamine Biosynthesis PE(18:0/20:4(5Z,8Z,11Z,14Z))516
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:0)514
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:0)515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:0)515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/24:0)515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/14:1(9Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/16:1(9Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:1(11Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:1(9Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:1(11Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:3(5Z,8Z,11Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:1(13Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/24:1(15Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:2(9Z,12Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:3(6Z,9Z,12Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:2(13Z,16Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:4(7Z,10Z,13Z,16Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:5(4Z,7Z,10Z,13Z,16Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:3(9Z,12Z,15Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:5(7Z,10Z,13Z,16Z,19Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))515
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:2(11Z,14Z))514
De Novo Triacylglycerol Biosynthesis TG(18:0/20:4(5Z,8Z,11Z,14Z)/20:3(8Z,11Z,14Z))514
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(18:0/20:4(5Z,8Z,11Z,14Z)) | PE(18:0/20:4(5Z,8Z,11Z,14Z))617

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346590Human TRPC6 (Transient Receptor Potential channels)1999Nature, Jan-21, Volume: 397, Issue:6716
Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol.
AID1346613Mouse TRPC2 (Transient Receptor Potential channels)2003Neuron, Oct-30, Volume: 40, Issue:3
A diacylglycerol-gated cation channel in vomeronasal neuron dendrites is impaired in TRPC2 mutant mice: mechanism of pheromone transduction.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's9 (33.33)18.2507
2000's9 (33.33)29.6817
2010's6 (22.22)24.3611
2020's3 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.85

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.85 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.85)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]